FTC's New Rule Zeroes In On More Pharma Patent Deals
The Federal Trade Commission revealed plans Monday to broaden the types of exclusive pharmaceutical patent rights licenses that require antitrust approval, part of the agency's continuing drive to scrutinize agreements that...To view the full article, register now.
Already a subscriber? Click here to view full article